Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The medicines being considered for reclassification are typically those that treat common, self-limiting conditions or those where the risk can be managed with pharmacy intervention
Cell 7 , 571583 (2004)
[PMID: 1560007] PubMed record related to this compound for laboratory literature review
The benzyl alcohol preservative stops bacterial growth after the vial is opened
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
US$ 27.83
US$ 21.46
US$ 29.85
US$ 29.35
US$ 25.41
US$ 23.25
US$ 24.22
US$ 21.54
US$ 23.25
